Trial Profile
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Cephalon
- 01 Dec 2015 Results published in the Annals of Hematology
- 28 May 2014 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov record.
- 02 Jul 2013 Planned end date changed from 1 Mar 2014 to 1 May 2014 as reported by ClinicalTrials.gov.